<SEC-DOCUMENT>0001193125-26-009642.txt : 20260112
<SEC-HEADER>0001193125-26-009642.hdr.sgml : 20260112
<ACCEPTANCE-DATETIME>20260112060255
ACCESSION NUMBER:		0001193125-26-009642
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20260111
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260112
DATE AS OF CHANGE:		20260112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MBX Biosciences, Inc.
		CENTRAL INDEX KEY:			0001776111
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42272
		FILM NUMBER:		26524524

	BUSINESS ADDRESS:	
		STREET 1:		11711 N. MERIDIAN STREET
		STREET 2:		SUITE 300
		CITY:			CARMEL
		STATE:			IN
		ZIP:			46032
		BUSINESS PHONE:		3179893100

	MAIL ADDRESS:	
		STREET 1:		11711 N. MERIDIAN STREET
		STREET 2:		SUITE 300
		CITY:			CARMEL
		STATE:			IN
		ZIP:			46032
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mbx-20260111.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-01-12T06:00:24.8801+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:mbx="http://www.mbxbio.com/20260111">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_46b54b01-0856-41e1-aba6-7db70480a9f2" name="dei:EntityCentralIndexKey" contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5">0001776111</ix:nonNumeric><ix:nonNumeric id="F_376f7ae2-9ecc-43df-8643-dcf8115e3d80" name="dei:AmendmentFlag" contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="mbx-20260111.xsd"/></ix:references><ix:resources><xbrli:context id="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776111</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-11</xbrli:startDate><xbrli:endDate>2026-01-11</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><h2 style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5f4daa7c-c637-4bf3-9917-d60b7548b6b1" contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></h2><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_cebf0441-12a0-444e-90cd-4c2b39b63334" contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">January 11, 2026</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9cebef14-ea02-4e75-b7ea-493ff540ce15" contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MBX Biosciences, Inc.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:18%;box-sizing:content-box;"/>
     <td style="width:41%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f96e6bca-3ac4-4b9a-a043-ccf4cf93f9f0" contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8800b665-b40f-423f-9df0-76cdd095cb27" contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-42272</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c0347d48-d983-454c-8ee6-61c407286ac2" contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">84-1882872</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission File Number)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_baf6a258-a18a-4030-a988-1435ab8b48ee" contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">11711 N. Meridian Street</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c89774a0-8877-41a1-a419-f10c8feccecb" contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 300</span></ix:nonNumeric></span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_6746bb42-ea36-4de1-8f8c-8dbf5870aa30" contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carmel</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_c4d970fa-3011-465b-b1e0-27b246878e81" contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Indiana</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_7db6520f-192d-4cad-a28a-f4e252d3ed6e" contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">46032</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_b165294b-766e-46b2-9b09-2509bf31408b" contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(317)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_54a46fc6-3701-4eb5-895c-a86694d0b374" contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">659-0200</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5f2daa70-8436-4a9c-b05e-ccd4d758e654" contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5" name="dei:EntityInformationFormerLegalOrRegisteredName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Not Applicable</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:3pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dc121bd2-bfc5-4269-931c-d74558420985" contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b4ff1cab-a499-4162-9db5-3425c5e69eec" contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2412839-3b8d-4551-acd2-cb592d072806" contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7c6e4072-4a03-4a5f-8bc2-abe507aaf7a9" contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:38%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:45%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Title of each class</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_34e3c767-04ef-432e-aebd-eeb17e0a2dbc" contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_73e4527d-d15d-49e5-9e17-3dfb7f4df8fb" contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MBX</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b5e6697d-8003-4944-bf43-e0d2f8b76085" contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_a6117437-9abc-4a9b-945d-4d7659752d61" contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;"><ix:nonNumeric id="F_80cf65c8-e646-4163-b5f7-782d1d7b4a7d" contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 11, 2026, MBX Biosciences, Inc. (the "Company" or "MBX Biosciences") disclosed that its unaudited cash, cash equivalents and marketable securities as of December 31, 2025 was $373.7 million, which is expected to fund operations into 2029. The information contained in Item 2.02 of this Form 8-K is unaudited and preliminary and does not present all information necessary for an understanding of the Company&#8217;s financial condition as of December 31, 2025. The audit of the Company&#8217;s consolidated financial statements for the year ended December 31, 2025 is ongoing and could result in changes to the information set forth above.</span></p><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7.01 Regulation FD Disclosure.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 11, 2026, the Company issued a press release (the "Press Release") titled "MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference". A copy of the Press Release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The information included under Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 8.01 Other Events.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future Development Plans</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 11, 2026, the Company announced that it expects to expand its obesity portfolio in 2026 with two additional obesity candidates, with nominations anticipated in the second quarter and third quarter of 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the Company&#8217;s current operating plan, the Company estimates that its cash, cash equivalents and marketable securities as of December 31, 2025 will be sufficient to fund its operations into 2029. The Company has based this estimate on assumptions that may prove to be wrong, and the Company could exhaust its available capital resources sooner than it expects.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">This Current Report on Form 8-K contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: MBX Biosciences&#8217; expectations regarding the expected timing of the announcement of additional obesity candidates in Q2 and Q3 2026; MBX Biosciences&#8217; preliminary unaudited cash, cash equivalents and marketable securities as of December 31, 2025; and expectations regarding MBX Biosciences&#8217; uses of capital, expenses and financial results, including the anticipated cash runway timing.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Forward-looking statements are based on management&#8217;s current expectations and are subject to risks and uncertainties that could negatively affect MBX Biosciences&#8217; business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to the Company&#8217;s research and development activities; MBX Biosciences&#8217; ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to preclinical and clinical development activities; the Company&#8217;s dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; MBX Biosciences&#8217; ability to attract, integrate and retain key personnel; risks related to the Company&#8217;s financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining MBX Biosciences&#8217; intellectual property protections; risks related to the competitive landscape for MBX Biosciences&#8217; product candidates; and final audit adjustments and other developments that may arise that would cause MBX Biosciences&#8217; expectations with respect to the estimate of cash, cash equivalents and marketable securities as of December 31, 2025 to differ, perhaps materially, from the financial results that will be reflected in MBX Biosciences&#8217; audited consolidated financial statements for the fiscal year ended December 31, 2025; as well as other risks described in &#8220;Risk Factors,&#8221; in MBX Biosciences&#8217; Quarterly Report on Form 10-Q for the three months ended September 30, 2025, Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC), as well as subsequent filings with the SEC. MBX Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Exhibits.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:22%;box-sizing:content-box;"/>
     <td style="width:78%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibit No.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="mbx-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press Release Issued by MBX Biosciences, Inc. on January 11, 2026</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:44%;box-sizing:content-box;"/>
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:46%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MBX BIOSCIENCES, INC.</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 12, 2026</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ P. Kent Hawryluk</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer (Principal Executive Officer)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>mbx-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-01-12T06:00:24.8237+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img258572290_0.jpg" alt="img258572290_0.jpg" style="width:242px;height:96px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Arial;font-kerning:none;min-width:fit-content;">MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026; Phase 3 initiation on track for Q3 2026</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">12-week data from Phase 1 trial of MBX 4291, a dual GLP-1/GIP co-agonist prodrug with potential for once-monthly dosing and improved tolerability for obesity, anticipated in Q4 2026</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Nomination of two additional obesity candidates expected in 2026: an amycretin prodrug and a GLP-1/GIP/GCGR triple agonist, each designed for once-monthly dosing</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Strong cash position: preliminary unaudited cash, cash equivalents and marketable securities of approximately $373.7 million as of December 31, 2025, expected to fund operations into 2029</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">CARMEL, Ind., January 11, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced it will provide an update on its clinical programs, expanding obesity pipeline, and outlook for 2026 during the Company&#x2019;s presentation at the 44</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Arial;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026, at 3:45 pm PT (6:45 pm ET). The live webcast can be accessed in the events section of the MBX Biosciences website at </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">https://investors.mbxbio.com/news-events/events</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;The Phase 2 success with once-weekly canvuparatide in chronic hypoparathyroidism sets the stage for our upcoming pivotal Phase 3 trial, while underscoring the broad clinical utility of our Precision Endocrine Peptide (PEP&#153;) platform,&#x201d; said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. &#x201c;We look forward to a catalyst-rich 2026, including the nomination of new development candidates in our expanding obesity portfolio and highly anticipated clinical data from MBX 4291, which holds the promise of potential once-monthly dosing with improved tolerability. With a strong cash position extending into 2029, we are well positioned to execute our strategy and continue to invest in long-term pipeline growth.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Once-weekly Canvuparatide for Hypoparathyroidism (HP)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The Phase 2 Avail&#153; trial (Avail) achieved its primary endpoint, demonstrating strong clinical proof-of-concept for canvuparatide with high responder rates and once-weekly dosing that was generally well-tolerated.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">MBX plans to share the full 12-week dataset from Avail and one-year follow-up data at a medical conference in Q2 2026. </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">An FDA End-of-Phase 2 meeting is planned for Q1 2026, as MBX continues to prepare for initiation of its Phase 3 confirmatory trial in Q3 2026. </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Primary market research supports canvuparatide&#x2019;s potential as a best-in-class therapy and new standard of care for patients with HP.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">MBX 4291 and Early Pipeline Programs for Obesity</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">MBX 4291, a glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic peptide (GIP) co-agonist prodrug with potential for once-monthly dosing, continues to progress through Phase 1 evaluation, with 12-week multiple ascending dose data expected in Q4 2026.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">MBX expects to expand its obesity portfolio in 2026 with two additional candidates designed to address the full spectrum of needs for patients with obesity, each with once-monthly dosing. These include an amycretin prodrug and a GLP-1/GIP/glucagon receptor (GCGR) prodrug candidate, with nominations anticipated in Q2 and Q3 2026.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Long-acting Imapextide (MBX 1416) for Post-Bariatric Hypoglycemia (PBH)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Results from the ongoing Phase 2a STEADI&#153; trial of potential once-weekly imapextide are expected in Q2 2026, including effects on post-prandial glucose regulation and related metabolic parameters.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Results from primary research conducted by MBX indicate that the majority of patients and endocrinologists surveyed prefer the convenience of a once-weekly injection over a once-daily injection in PBH.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Strong Cash Position</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Preliminary unaudited cash, cash equivalents and marketable securities of approximately $373.7 million as of December 31, 2025, are expected to fund operations into 2029. </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">About MBX Biosciences<br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">MBX Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP&#153; platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company&#x2019;s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) preparing for Phase 3 development; an obesity portfolio that includes MBX 4291 in Phase 1 development, as well as multiple discovery and pre-clinical obesity candidates; and imapextide (MBX 1416) for the treatment of post-bariatric hypoglycemia (PBH) in Phase 2 development. The Company is based in Carmel,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Indiana. To learn more, please visit the Company website at </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">www.mbxbio.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> and follow it on </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">LinkedIn</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">About MBX&#x2019;s Proprietary Precision Endocrine Peptide (PEP&#153;) Platform</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">MBX was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, the Company designed its proprietary Precision Endocrine Peptide&#153; (PEP&#153;) platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients. PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">This press release contains &#x201c;forward-looking statements&#x201d; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;plan,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;would&#x201d; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: MBX Biosciences&#x2019; expectations regarding the clinical development of canvuparatide, including timing of the one-year follow-up data from the Phase 2 trial in Q2 2026, timing of FDA End-of-Phase 2 and EMA Scientific Advice meetings in Q1 2026 and timing of initiation of a Phase 3 trial in Q3 2026; the potential for canvuparatide to be a best-in-class, once-weekly PTH replacement therapy and a new standard of care for patients with HP; the expected timing of results from the Phase 2a trial for imapextide; statements related to the ability of imapextide to be a treatment of PBH; expectations on patient and endocrinologist preference for a once-weekly over a once-daily treatment; the expected timing of results from the Phase 1 trial for MBX 4291 in Q4 2026; the potential for MBX 4291 to be dosed once-monthly with improved tolerability; the expected timing of the announcement of additional obesity candidates in Q2 and Q3 2026; MBX Biosciences&#x2019; preliminary unaudited cash, cash equivalents and marketable securities as of December 31, 2025; and expectations regarding MBX Biosciences&#x2019; uses of capital, expenses and financial results, including the anticipated cash runway timing.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Forward-looking statements are based on management&#x2019;s current expectations and are subject to risks and uncertainties that could negatively affect MBX Biosciences&#x2019; business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to the Company&#x2019;s research and development activities; MBX Biosciences&#x2019; ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to preclinical and clinical development activities; the Company&#x2019;s dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; MBX Biosciences&#x2019; ability to attract, integrate and retain key personnel; risks related to the Company&#x2019;s financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining MBX Biosciences&#x2019; intellectual property protections; risks related to the competitive landscape for MBX Biosciences&#x2019; product candidates; and final audit adjustments and other developments that may arise that would cause MBX Biosciences&#x2019; expectations with respect to the estimate of cash, cash equivalents and marketable securities as of December 31, 2025 to differ, perhaps materially, from the financial results that will be reflected in MBX Biosciences&#x2019; audited consolidated financial statements for the fiscal year ended December 31, 2025; as well as other risks described in &#x201c;Risk Factors,&#x201d; in MBX Biosciences&#x2019; Quarterly Report on Form 10-Q for the three months ended September 30, 2025, Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC), as well as subsequent filings with the SEC. MBX Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">MBX Biosciences uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company's Investor Relations website, in addition to following the Company's press releases, SEC filings, public conference calls, presentations, and webcasts.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Financial Disclosure Advisory</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">MBX Biosciences has not yet completed its year-end financial close process for the fiscal year ended December 31, 2025. The estimate of the Company&#x2019;s cash, cash equivalents and marketable securities as of December 31, 2025 is preliminary, has not been audited and is subject to change upon completion of the Company&#x2019;s financial statement closing procedures. Additional information and disclosure would be required for a more complete understanding of the Company&#x2019;s financial position and results of operations as of December 31, 2025. The Company&#x2019;s independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to this preliminary result and, accordingly, does not express an opinion or any other form of assurance about it.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Media Contact:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Cassidy McClain</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Inizio Evoke Comms</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0563c1;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">cassidy.mcclain@inizioevoke.com</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">   </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">(619) 694-6291</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Investor Contact:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Jim DeNike</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">MBX Biosciences</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0563c1;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">jdenike@mbxbio.com</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img258572290_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img258572290_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "K ;$# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;X*_'"_V0:?X*\0:M#J/ASQG=X;,7@3Q:;;3DO\ 4I @E'AG6-/TK6B91!I
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M$?U%X-?\(D,/AZWN?VY!UJW-HHUG%3P2?7^#'V:B]JN(EHKL^"?^#AS]H_\
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MO<7NI:IJ=_+!9V%C:01O-<W5U-%!#$C/(ZJ":_AT_P"'W_\ P45_Z*SX6_\
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M_P"7G+%+!+)!/')#-#(\4T,J-'+%+&Q22.2-P'CDC<%71@&5@58 @BO[,?\
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MB_>A#!X>K]8^KOK[&4OJ^ CM:-6"5K7/WL^+O@"S^*_PH^)OPNU!HTL?B/\
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MO"/ARREU/Q#XIUS2?#FA:= "T^H:SKE_;Z9I=E"H!+2W=]=001@ DO(!BO\
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M'_%>A:OX;UVP9WB6]T;7=/N-+U.T:2)DEC%S974\)>-E= ^Y&# $?R?^.?\
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M4DL."M])I>L+!(2IT^X4;V_H0_9-_8<_9V_8O\,W&A_!;P?]GUK5;>*#Q/\
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MN1U.&,.^>ADD\OH2P-"KSU*GUBE2<+T\4ZE6K4EBX26)E4JU9RJN52;E\/\
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G %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>mbx-20260111.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-01-12T06:00:25.1965+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.mbxbio.com/20260111" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:mbx="http://www.mbxbio.com/20260111" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="mbx-20260111.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Information, Former Legal or Registered Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10200.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName" order="10150.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 11, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 11,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MBX Biosciences, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001776111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-42272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-1882872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11711 N. Meridian Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carmel<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">46032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(317)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">659-0200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">Not Applicable<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MBX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>25</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mbx-20260111.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="mbx-20260111.htm">mbx-20260111.htm</File>
    <File>mbx-20260111.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>12
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "mbx-20260111.htm": {
   "nsprefix": "mbx",
   "nsuri": "http://www.mbxbio.com/20260111",
   "dts": {
    "inline": {
     "local": [
      "mbx-20260111.htm"
     ]
    },
    "schema": {
     "local": [
      "mbx-20260111.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 25,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 26,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 25
   },
   "report": {
    "R1": {
     "role": "http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mbx-20260111.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mbx-20260111.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.mbxbio.com/20260111/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0001193125-26-009642-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-009642-xbrl.zip
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M<G03]EAVQ3%FA*]UW[1:" 6#%%Q;AL;BM#&)TT-P@&SP+05G,:]*Z9'N*<C
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M^_@,#@ N%GD?OLRA>3U[A'C*:91BLUM/6N7?D2WSN08ZY@:90'V,*<-6) 2
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M3AL_**. 7%#@J$Q5T>KPZ* SBXA6!DP6%;&D7ZBC$%LG)@J5="O9EUH#-44
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M=&WM/6MWVS:RW_LKL.GMUCY7E"W9<6K)S5G'=A[=/)0X>[K?[H%(2$),$BP
M2E9__9T9@"\]7">Q:R=63UO;) A@!O.> 7#TCR!@I\]?O67'H953<2I-&"N3
M:\&VSM]LLY<?W[QFIRK,$Y%:%K")M5EO9V<VF[6CD4R-BG,K56K:H4IV6! \
M/<(.3[3@^)B=<BM8K[O;/0AV.T&G^W'WH+>[V^ONMW_I[CWY7_AU=[?Z2F5S
M+<<3R[;";88?P<AI*N)8S-ESF?(TE#QFY\68+?8J#=OL.([9!_S,L _""#T5
M41O[_.%H8I/XZ0_L:")X!#_9D94V%D_/_AL<'K8[1SON3VBPXUL<#54T9\;.
M8_'KHXQ'D4S'O5^RRW["]5BF/9Y;]0^99$I;GMK^GX%,(W'9V^T',S&\D#:P
MXM(&1OXI AY]RHWM=79W?^IGRDB<<4^+F".6^X]H.I&<+@P66)7U=MN/95IV
MWNTG,@TF B'L=>#%<F]#=8F#XF2'2D="!_ $QCC*BNY'*G7S@@EEUH/C!NO3
MNQ%/9#SO?92),.RMF+$/*N%IT7"HK%4)M"7X>"S',#I.J&@0BY&%U_XO>@5_
MP@RP\V(2H8J5[OVX2__T9Q-I16 R'HI>ID4PTSQS<YDY6(<JCOH+$[]JKO3N
M0N@4\9"J5!#B9C*RD]X(UB:$]T#$,*NSRXD<2LL<%>!W3X]V,O@/%J1<F##F
MQOSZ*.'0B?^4?L+?0C\J8"I6Z?'*1;[5!4"<XQ@R&3.CPU\?P2_=Q[\\?M+M
M'N[^WV[[4S9^Q'AL5[_P\W+HZ>YW@<@]C1T>9$0\B)';G'\(&!7ZAHED?X%(
MCC6(C,\@C3?/_LN>265"*=(0(+&*#;2:RD@X@?0NM[%2%XRG$7N6&Z %8]A_
ML@CE'+=L?]].V'&:YB"G?FL/VNR-TF.>LI<"%F(2<A"K)RH="8V]UTFO1'2=
MH?;:>WM[/RWRP.WA?CVVW>B=KT3N/W_L'.SV-V#?#["ORVE_B03JKR<M#!9^
M!EK>I2*8"Z[92,6QF@5YQH"-.!MIE;#!A!M@.69Q&*9&3 '# -.+BWC.0IY.
M\XQK$+.1:#'.,H5]8LNA,#9 B8W2F]F) ##F,()FDWFFZ)O)7"L929/ E_!1
M*#-@WHC)E+WO$I/W_>A[\ Q$NK-DX%^K>7A!?;W?HX;%DMX<5G\^ 20.M?RY
M97AJ K!FY.@S4'HTU$_OW:0VY+\2+9TND?,2S7<JFD=EM-\]["")1ZA27KP>
M!)V=%Z\&+%0!'ZM4&LLRK2*=C]E,@NZI. 'IE)@F@2$GP#41&"CIF#07F+"@
MU(#HK8J!0X8REM9QB0(&@M^766._0?%W8QML!/6=4.I;!6^\%!PQ.U,,G17\
M&\G4$0S*Y$BB&628N,Q$Z.D&B:8'Q,1X,@^UL/"HH%<D1%Z1],Z+DQ<?D/:S
M&$PI1]LM)G@X81$,,4ZAPS4T_6"I\L&0X+G5"F17R V*..]H 26)6")MZCG+
M4YX#40*18*.6:RK^R.64Q]"'(7(#N"^$Y4.@,"/"7$,_@!<@:IX!55[*!.@7
MJ.I_]I[LM9\PF'N,1,^IR:D(13(4FNV!/ :R?MRJ"!V\A%$._:M,:&(4 [0/
M#Z'9X=^U<(4[^/V2YL.$\,98[UKPGAQ_>'/V&B-K4;O%?N/@R0)S=1S)'["M
M%Z_?/3MC;\]^/__]U8>S;18$;,%E]E&YK;?<1/R/'K[>1@,FC,&:#GD,(H"/
M!1M*E4VX3@"0W.)S,&F2C*=HAH2Y :9"BWLB&%CJ(=@J&FR22$Q%K#(*12([
MPQ>)T!@4E'^6^BF%QC&*AE :?)2)#-T$[PL@OZ,6P9XM1BFI,_A,I)$*-?CS
M3E"@E% @HW!X"JD!7%9%? ZO4Y4#H*#>+-A<,8[E @2@Y7(7"8!A)8B< F1L
M,=8\,20R4%&"+"L49R8SD&(I^C$H07Q\ >=(&(] 2D%KG.^)0] _?[SL[G8.
M^P:!-#!]!SJWU&A__PL= $ QK8,G19.#+*M1UI/VWI.OI"T[N7G?Y'/G<.W@
M#!HOY_#RN<:P,Y @+NK'7 !1SVN,L><8HX7HW^OM/V89V/$?V=:!__WLXW:;
M?81UB>54L)D8@EZR:"R!I\IX"/QBG*&$:P?DC9H*5%-I;,'3Q9 4= *$0^&F
M.C[_7KF(>0#3V]F1Z10\;J5-.QE> D]3'B 5,Q,X8';<CU* WO7ZMS?*ZOM1
M5DX2AGWDKR)@9')B*N<-KPT:(<>%$[ I0<(O!X:  RT%CYC35>1VY!JD>XBN
MT!AD]E2!"5O&B<AC;S& %RQ+, 1!782JE-M#K7A4*0-0=^1N8U +.AV4FNJL
M5$$#K[.V!F<#6-3'>_UMEL7<PD22EH,ZZC/#9<3^C?KK)9_I>9Q?M+ W U]Z
M!7DRD6+$SB[!UL6,!'LW&LD03%@?6ZA)E38KD/D[R"JO@69<DVT+RIL#N'-C
M RW!'W,23Z9AG$<%D&G#200)T-#6->\0,(]@KU"$2@. 8''3U"=RC Y>/0Q1
M8K *F501$L ]S&RBXLBM'*C<1,+BP&2JF,BJ> @1RLJ 2)O]CN\X4,&R]P$
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M              "  0    !M8G@M,C R-C Q,3$N:'1M4$L! A0#%     @
M6C L7&LTJ G\"   2VD  !               ( !/!L  &UB>"TR,#(V,#$Q
M,2YX<V102P$"% ,4    " !:,"Q<L+X'U[L6  !!E   #@
J@ %F)   ;6)X+65X.3E?,2YH=&U02P4&      ,  P"X    33L

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>mbx-20260111_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mbx-20260111.xsd" xlink:type="simple"/>
    <context id="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776111</identifier>
        </entity>
        <period>
            <startDate>2026-01-11</startDate>
            <endDate>2026-01-11</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5"
      id="F_46b54b01-0856-41e1-aba6-7db70480a9f2">0001776111</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5"
      id="F_376f7ae2-9ecc-43df-8643-dcf8115e3d80">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5"
      id="F_5f4daa7c-c637-4bf3-9917-d60b7548b6b1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5"
      id="F_cebf0441-12a0-444e-90cd-4c2b39b63334">2026-01-11</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5"
      id="F_9cebef14-ea02-4e75-b7ea-493ff540ce15">MBX Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5"
      id="F_f96e6bca-3ac4-4b9a-a043-ccf4cf93f9f0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5"
      id="F_8800b665-b40f-423f-9df0-76cdd095cb27">001-42272</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5"
      id="F_c0347d48-d983-454c-8ee6-61c407286ac2">84-1882872</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5"
      id="F_baf6a258-a18a-4030-a988-1435ab8b48ee">11711 N. Meridian Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5"
      id="F_c89774a0-8877-41a1-a419-f10c8feccecb">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5"
      id="F_6746bb42-ea36-4de1-8f8c-8dbf5870aa30">Carmel</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5"
      id="F_c4d970fa-3011-465b-b1e0-27b246878e81">IN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5"
      id="F_7db6520f-192d-4cad-a28a-f4e252d3ed6e">46032</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5"
      id="F_b165294b-766e-46b2-9b09-2509bf31408b">(317)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5"
      id="F_54a46fc6-3701-4eb5-895c-a86694d0b374">659-0200</dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName
      contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5"
      id="F_5f2daa70-8436-4a9c-b05e-ccd4d758e654">Not Applicable</dei:EntityInformationFormerLegalOrRegisteredName>
    <dei:WrittenCommunications
      contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5"
      id="F_dc121bd2-bfc5-4269-931c-d74558420985">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5"
      id="F_b4ff1cab-a499-4162-9db5-3425c5e69eec">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5"
      id="F_d2412839-3b8d-4551-acd2-cb592d072806">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5"
      id="F_7c6e4072-4a03-4a5f-8bc2-abe507aaf7a9">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5"
      id="F_34e3c767-04ef-432e-aebd-eeb17e0a2dbc">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5"
      id="F_73e4527d-d15d-49e5-9e17-3dfb7f4df8fb">MBX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5"
      id="F_b5e6697d-8003-4944-bf43-e0d2f8b76085">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5"
      id="F_a6117437-9abc-4a9b-945d-4d7659752d61">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_f1da4e99-906d-439b-bbfa-ddfb9c10ddd5"
      id="F_80cf65c8-e646-4163-b5f7-782d1d7b4a7d">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
